Press Release: Novartis remibrutinib, a -2-

Novartis

137.14 EUR 4.37%

• Charts
• News
• Analysen

Kaufen Verkaufen

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 300 million people worldwide.

Reimagine medicine with us: Visit us at https://www.novartis.com/ www.novartis.com and connect with us on https://www.linkedin.com/company/novartis/ LinkedIn, https://www.facebook.com/novartis/ Facebook, https://twitter.com/Novartis X/Twitter and https://instagram.com/novartis?igshid=MzRlODBiNWFlZA==__;!!N3hqHg43uw!pjp8z253J5NjaOYrW65UbAAlHeHRdQ-w0m4ezZxEQEl0ptafXN2M99VRIk39pf49PAc8NbK93Pxp3uaSBQkAf8oEnzWXG8Sk$ Instagram.

References

1. Data on file

2. Metz M, Giménez-Arnau AM, Hide M, et al. Remibrutinib in chronic

spontaneous urticaria. N Engl J Med. 2025;392(10):984-994.

doi:10.1056/NEJMoa2408792

3. Giménez-Arnau AM, Szalewski R, Hide M, et al. Remibrutinib in

chronic spontaneous urticaria: 52-week results from two phase 3

studies. J Allergy Clin Immunol. 2026;157(1):143-154.

doi:10.1016/j.jaci.2025.09.028

4. Novartis. Novartis remibrutinib first therapy to achieve Phase III

primary endpoint in chronic inducible urticaria (CIndU). Novartis US.

Published February 18, 2026. Available

from: https://www.novartis.com/us-en/news/media-releases/novartis-remibru

tinib-first-therapy-achieve-phase-iii-primary-endpoint-chronic-inducible-

urticaria-cindu Last accessed: August 6, 2026

5. Ferreira HB, Neves B, Guerra IM, Moreira A, Melo T, Paiva A, Domingues

MR. An overview of lipidomic analysis in different human matrices of

multiple sclerosis. Mult Scler Relat Disord. 2020;44:102189.

doi:10.1016/j.msard.2020.102189

6. Portaccio E, Magyari M, Kubala Havrdova E, et al. Multiple sclerosis:

emerging epidemiological trends and redefining the clinical course.

Lancet Reg. Health Eur. 2024;44:100977.

7. National Multiple Sclerosis Society. Types of MS. Available

from: https://www.nationalmssociety.org/What-is-MS/Types-of-MS Last

accessed: July 15, 2026

8. Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of

multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278-286.

doi:10.1212/WNL.0000000000000560

9. Angst D, Gessier F, Janser P, et al. Discovery of LOU064 (Remibrutinib),

a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine

Kinase. J Med Chem. 2020;63(10):5102-5118.

doi:10.1021/acs.jmedchem.9b01916

10. Kaul M, End P, Cabanski M, et al. Remibrutinib (LOU064): A selective

potent oral BTK inhibitor with promising clinical safety and

pharmacodynamics in a randomized phase I trial. Clin Transl Sci.

2021;14(5):1756-1768. doi:10.1111/cts.13005

11. Jain RW, Rayatpour A, Hagen K, et al. Investigations of remibrutinib in

models pertinent to multiple sclerosis. Neurotherapeutics.

2026;23(3):e00923. doi:10.1016/j.neurot.2026.e00923

12. Nuesslein-Hildesheim B, Ferrero E, Schmid C, et al. Remibrutinib (LOU064)

inhibits neuroinflammation driven by B cells and myeloid cells in

preclinical models of multiple sclerosis. J Neuroinflammation.

2023;20(1):194. Published 2023 Aug 26. doi:10.1186/s12974-023-02877-9

13. ClinicalTrials.gov. NCT03827798. Study of efficacy and safety of

investigational treatments in patients with moderate to severe

hidradenitis suppurativa. Available

from: https://clinicaltrials.gov/ct2/show/NCT03827798. Last accessed:

July 2026

14. ClinicalTrials.gov. NCT05432388. Study of efficacy, safety and

tolerability of remibrutinib in adult participants with an allergy to

peanuts. Available

from: https://clinicaltrials.gov/study/NCT05432388 Last accessed: July

2026

15. Novartis. Novartis receives FDA approval for Rhapsido(R) (remibrutinib),

the only oral, targeted BTKi treatment for chronic spontaneous urticaria

(CSU). News release. Novartis. September 30, 2025. Available from:

https://www.novartis.com/news/media-releases/novartis-receives-fda-approval-rhapsido-remibrutinib-only-oral-targeted-btki-treatment-chronic-spontaneous-urticaria-csu

Last accessed: August 6, 2026

16. Novartis. Novartis Rhapsido(R) receives European Commission approval as

first oral targeted treatment for chronic spontaneous urticaria. News

release. Novartis. April 27, 2026. Available

from: https://www.novartis.com/news/media-releases/novartis-rhapsido-rece

ives-european-commission-approval-first-oral-targeted-treatment-chronic-s

pontaneous-urticaria Last accessed: August 6, 2026

17. ClinicalTrials.gov. NCT05147220. Efficacy and safety of remibrutinib

compared to teriflunomide in participants with relapsing multiple

sclerosis (RMS) (REMODEL-1). Available from:

https://clinicaltrials.gov/study/NCT05147220 Last accessed: July 2026

18. ClinicalTrials.gov. NCT05156281. Efficacy and safety of remibrutinib

compared to teriflunomide in participants with relapsing multiple

sclerosis (RMS) (REMODEL-2). Available from:

https://clinicaltrials.gov/study/NCT05156281 Last accessed: July 2026

19. Wiendl H, Airas L, Chitnis T, et al. Phase 3 REMODEL I/II Trials:

Efficacy, Safety, and Tolerability of Remibrutinib in Patients with

Relapsing Multiple Sclerosis. Mult Scler Relat Disord. 2023;80:105315.

doi:10.1016/j.msard.2023.105315

# # #

Novartis Media Relations

E-mail: media.relations@novartis.com

Novartis Investor Relations

Central investor relations line:

+41 61 324 7944

E-mail: investor.relations@novartis.com

(END) Dow Jones Newswires

September 01, 2026 01:15 ET (05:15 GMT)